The table below shows Monte Rosa Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$4.21M
$12.77M
$23.19M
$84.93M
$9.22M
$4.70M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$44.07M
$36.68M
$30.65M
$32.19M
$27.62M
$28.05M
SG&A
GLUE annual revenue (10-K history)
Monte Rosa Therapeutics, Inc. reported annual revenue of $123.67M for fiscal year 2025. That is up 63.5% from $75.62M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
